1 Correction to: Clinical Drug Investigation (2018) 38:853–865 https://doi.org/10.1007/s40261-018-0678-5
The Open Access license, which previously read:
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Should read:
Open Access
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s)and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Sangroongruangsri, S., Chaikledkaew, U., Kumluang, S. et al. Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study. Clin Drug Investig 39, 115 (2019). https://doi.org/10.1007/s40261-019-00747-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-019-00747-y